<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841720</url>
  </required_header>
  <id_info>
    <org_study_id>HSK16149-103</org_study_id>
    <nct_id>NCT04841720</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride Tablets</brief_title>
  <official_title>Phase I Clinical Study to Evaluate the Drug-drug Interaction Between HSK16149 Capsules and Metformin Hydrochloride Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Fourth Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open, single-arm study, conducted in healthy Chinese&#xD;
      populations, and plans to enroll 22 healthy adult subjects (the ratio of either sex is not&#xD;
      less than 1/3).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects received the following drugs:&#xD;
&#xD;
      Phase 1-HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only&#xD;
      oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4&#xD;
      days (D5-D8); Phase 2-Metformin hydrochloride tablets for single use: D9-D11 oral metformin&#xD;
      hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the&#xD;
      morning on an empty stomach; wash-out period is about 4 days (D12-D15); Phase 3-Combined use&#xD;
      of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin&#xD;
      hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin&#xD;
      hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>Peak concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t, AUC0-∞</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>-30 minutes before administration until 24 hours after administration</time_frame>
    <description>time to peak observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE/serious AE</measure>
    <time_frame>From screening up to 6 weeks</time_frame>
    <description>Adverse event/serious adverse event</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <condition>Diabetic Neuropathy Peripheral</condition>
  <arm_group>
    <arm_group_label>HSK16149</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSK16149（D1-D5）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HSK16149+Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSK16149+Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149</intervention_name>
    <description>HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);</description>
    <arm_group_label>HSK16149</arm_group_label>
    <other_name>HSK16149（phase 1）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride tablet</intervention_name>
    <description>Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin hydrochloride tablets（phase 2）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK16149+Metformin（phase 3）</intervention_name>
    <description>Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.</description>
    <arm_group_label>HSK16149+Metformin</arm_group_label>
    <other_name>HSK16149 capsules and Metformin hydrochloride tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-50 years old (including 18 and 50 years old), healthy male or female;&#xD;
&#xD;
          2. Weight: male ≥50 kg, female ≥45kg; body mass index (BMI) in the range of 19-28kg/m2&#xD;
             (including 19 and 28);&#xD;
&#xD;
          3. Serum creatinine during the screening period is within the normal range, or creatinine&#xD;
             clearance rate (CCr) ≥80mL/min;&#xD;
&#xD;
          4. Physical examination, vital signs, 12-lead electrocardiogram (ECG), chest X-ray&#xD;
             (posterior anterior position), and laboratory examination indicators are normal or&#xD;
             abnormal and have no clinical significance;&#xD;
&#xD;
          5. Agree to have no birth plan and be able to take reliable contraceptive measures within&#xD;
             3 months after the end of the trial; Be able to communicate well with researchers,&#xD;
             fully understand the purpose and requirements of this trial, voluntarily participate&#xD;
             in clinical trials and sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who are known to have a history of allergies, allergic diseases or allergies to&#xD;
             the research preparation and any of its ingredients or related preparations, or those&#xD;
             who have a history of pregabalin or gabapentin allergy;&#xD;
&#xD;
          2. Those who have special requirements for diet and cannot comply with a unified diet;&#xD;
&#xD;
          3. Those who have had angioedema in the past;&#xD;
&#xD;
          4. Clinically significant dizziness or vertigo, or a history of inner ear diseases known&#xD;
             to cause dizziness or vertigo;&#xD;
&#xD;
          5. QTcF&gt;450 milliseconds (msec) found in the screening period inspection;&#xD;
&#xD;
          6. People with insomnia, anxiety disorder, depression disorder or other mental disorders;&#xD;
&#xD;
          7. Those who use any caffeine-rich food or drink (coffee, tea, cola, chocolate, etc.)&#xD;
             within 48 hours before the first administration of the test drug, or who do not agree&#xD;
             to prohibit the use of any caffeine-rich food or drink during the test period ；&#xD;
&#xD;
          8. Any disease history or current disease that may affect the safety evaluation of&#xD;
             subjects or the internal process of experimental drugs, including the central nervous&#xD;
             system, cardiovascular system, digestive system, respiratory system, urinary system,&#xD;
             blood system, immunology, Psychiatry, metabolic abnormalities, gastrointestinal&#xD;
             surgery (except appendicitis surgery), etc.;&#xD;
&#xD;
          9. Those who donate blood or lose blood ≥400 mL or have blood transfusion within 3 months&#xD;
             before the first administration of the test drug;&#xD;
&#xD;
         10. Any drug that inhibits or induces liver drug-metabolizing enzymes (such as inducers&#xD;
             barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole) has been used&#xD;
             within 30 days before the first administration of the test drug; Serotonin reuptake&#xD;
             inhibitor (SSRI) antidepressants, cimetidine, diltiazem macrolides, nitroimidazoles,&#xD;
             sedative hypnotics, verapamil, fluoroquinolones, antihistamines), or Any prescription&#xD;
             drugs, over-the-counter drugs and herbal medicines other than the above-mentioned&#xD;
             drugs were taken within 14 days prior to the administration of the test drugs;&#xD;
&#xD;
         11. Those who have participated in other drug clinical trials within 3 months before the&#xD;
             first administration of the experimental drug;&#xD;
&#xD;
         12. At this stage or have been drug users, or those who have been screened positive for&#xD;
             drug abuse (screening items include: morphine, tetrahydrocannabinolic acid,&#xD;
             methamphetamine, dimethylenedioxyamphetamine, Ketamine and cocaine);&#xD;
&#xD;
         13. Alcoholics or frequent alcoholics in the 3 months before the test, that is, drinking&#xD;
             more than 21 units of alcohol per week (1 unit = 360mL beer or 45 mL 40% alcoholic&#xD;
             spirits or 150 mL wine), or alcohol exhalation Test value&gt; 0mg/ml;&#xD;
&#xD;
         14. Smokers or those who smoked more than 10 cigarettes per day within 3 months before the&#xD;
             first administration, or who could not comply with the ban on smoking during the trial&#xD;
             period;&#xD;
&#xD;
         15. One or more of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody,&#xD;
             syphilis antibody or human immunodeficiency virus (HIV) antibody is positive;&#xD;
&#xD;
         16. Women during pregnancy or lactation;Researchers believe that subjects have poor&#xD;
             compliance or other factors that are not suitable for participating in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingxia Wang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Ethics Committee of theThe fourth hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kai Chen, PhD</last_name>
    <phone>028-82378557</phone>
    <email>chenk@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The fourth hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxia Wang, PhD</last_name>
      <phone>0331-86095794</phone>
      <email>Dgyxxli@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

